European Medicines Agency Begins Evaluation of Marketing Application for Sublingual Sufentanil 30 mcg Tablet (ARX-04) for Moderate-to-Severe Acute Pain

Tuesday, March 28, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

CHMP Opinion Expected First Half 2018



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store